Andrea Eleazar, MHS

A new trial shows that the combination of belzutifan and lenvatinib improves progression-free survival in advanced renal cell carcinoma patients.

FDA designates ZEN-3694 as an orphan drug, offering hope for patients with NUT carcinoma with no current approved therapies.

A groundbreaking study reveals promising efficacy and safety of 212Pb-DOTAMTATE for treating neuroendocrine tumors, paving the way for future trials.

A recent trial evaluates the impact of dostarlimab on ovarian cancer treatment, revealing modest benefits and no significant safety concerns with niraparib.

The FDA designates daraxonrasib as an orphan drug for pancreatic cancer, targeting RAS mutations with promising trial results.

The FDA fast-tracks JSKN003, a promising treatment for platinum-resistant ovarian cancer, enhancing development and approval processes for this critical therapy.

GLP-1 receptor agonists show promise in treating various chronic conditions, but potential risks and unanswered questions remain for care of patients with NETs.

Recent findings from the MIRASOL trial reveal significant advancements in treatment options for platinum-resistant ovarian cancer, emphasizing effective therapy sequencing.

A study reveals that obesity and sex significantly influence liver recurrence and survival rates in pancreatic cancer patients post-surgery.

New research highlights narsoplimab's potential to significantly reduce mortality in high-risk patients with thrombotic microangiopathy after stem cell transplants.

Results of a recent study reveal significant racial differences in renal cell carcinoma histology and outcomes, highlighting the need for ancestry-informed kidney care strategies.

Revumenib gains FDA approval for treating relapsed mNPM1 AML, showcasing promising efficacy and safety data from the AUGMENT-101 trial.

The FDA fast tracks MT-125, a promising new treatment for glioblastoma, enhancing patient care and expediting drug development.

New research reveals that sustained MRD negativity after ASCT allows safe discontinuation of lenalidomide maintenance in multiple myeloma patients.

The FDA fast-tracks pamlectabart tismanitin, a promising treatment for relapsed multiple myeloma, enhancing its development and review process.

New findings reveal that adding sapanisertib to weekly paclitaxel significantly improves progression-free survival in advanced ovarian cancer patients.

Vishal A. Patel, MD, discusses the FDA approval of cemiplimab in cutaneous squamous cell carcinoma.

FDA prioritizes review of enfortumab vedotin and pembrolizumab for muscle-invasive bladder cancer, showing promising results in reducing recurrence and mortality.

The FDA reviews XS003, a new nilotinib formulation for CML, promising improved safety and convenience for patients.

A groundbreaking study reveals the effectiveness of dabrafenib and trametinib in treating advanced thyroid cancer, showcasing significant survival benefits.

Combination therapy of percutaneous hepatic perfusion with immune checkpoint inhibitors shows promising survival rates in metastatic uveal melanoma patients.

New findings from the EMBARK trial reveal enzalutamide significantly reduces mortality risk in high-risk prostate cancer patients, enhancing treatment options.

Early-stage cervical cancer treatment significantly boosts survival rates in older patients, highlighting the need for tailored care strategies.

Sacituzumab tirumotecan significantly improves progression-free survival in HR+/HER2– breast cancer compared with traditional chemotherapy.

Durvalumab combined with FLOT chemotherapy significantly enhances overall survival in resectable gastric adenocarcinoma, establishing a new standard of care.

A new study reveals serplulimab significantly improves event-free survival in gastric cancer, offering a promising alternative to traditional chemotherapy.

FDA fast-tracks EO2463 immunotherapy for follicular lymphoma, promising a new treatment option backed by positive trial data and innovative technology.

Medicaid expansion significantly improves long-term cancer survival rates, especially for vulnerable populations, highlighting the need for broader adoption across states.

The FDA fast-tracks NG-350A, an innovative immunotherapy for advanced rectal cancer, aiming to enhance treatment options and patient outcomes.

The FDA designates ficerafusp alfa as a breakthrough therapy for treating HPV-negative head and neck cancer, enhancing patient outcomes and options.